Mark Jenkins
Keine laufenden Positionen mehr
Profil
Mark Jenkins is the founder of Jenarron Therapeutics Ltd.
which was founded in 2012.
Ehemalige bekannte Positionen von Mark Jenkins
| Unternehmen | Position | Ende |
|---|---|---|
Jenarron Therapeutics Ltd.
 Jenarron Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Jenarron Therapeutics Ltd. has developed an innovative product for the treatment of minor cuts and grazes. The company is based in the UK and was founded in 2012 by Mark Jenkins, Paul A. McCarron, Ryan Loughlin. The British company's patented 'rheogel' formulation contains 2% lidocaine, which is effective for pain relief and pain-free wound cleaning in OTC settings. The rheogel flows to form an effective barrier, preventing further wound contamination, and is dry to the touch with a viscoelastic structure that makes it resistant to impact and penetration. The product is child-friendly, with no stinging on application, and has an immediate cooling and soothing effect. | Gründer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Jenarron Therapeutics Ltd.
Jenarron Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Jenarron Therapeutics Ltd. has developed an innovative product for the treatment of minor cuts and grazes. The company is based in the UK and was founded in 2012 by Mark Jenkins, Paul A. McCarron, Ryan Loughlin. The British company's patented 'rheogel' formulation contains 2% lidocaine, which is effective for pain relief and pain-free wound cleaning in OTC settings. The rheogel flows to form an effective barrier, preventing further wound contamination, and is dry to the touch with a viscoelastic structure that makes it resistant to impact and penetration. The product is child-friendly, with no stinging on application, and has an immediate cooling and soothing effect. | Health Technology |
